RxDoctor Payments DataLook up a doctor →

Richard Hammond, MD

Neurology · Twin Falls, IDNPI 1558306589

Payments from drug & device makers

$16,162in general payments, 2019–2025

Across 987 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • EMD Serono, Inc.$2K
  • UCB, Inc.$947
  • SK Life Science, Inc.$778
  • Novartis$647
  • Bristol Myers Squibb$624
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$270%
  • Speaking & faculty fees$1061%
  • Travel & lodging$2331%
  • Food & beverage$15,76898%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,162 in reported general payments places this provider in the 80th percentile of 59 neurology providers in Idaho.

See all neurology providers in Idaho

Medicare billing

Part B allowed, 2024
$75,205
Medicare patients
472
Services billed
1,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate23$439,233
XcopriCenobamate199$236,206
GammakedImmune Globul G/Gly/Iga Avg 4620$221,871
BriviactBrivaracetam149$199,713
NuplazidPimavanserin Tartrate26$120,715
EpidiolexCannabidiol (Cbd)14$113,398
AptiomEslicarbazepine Acetate62$107,180
Avonex (4 Pack)Interferon Beta-1a13$102,902
ZeposiaOzanimod Hydrochloride12$99,734
QuliptaAtogepant74$80,290
RytaryCarbidopa/Levodopa47$66,185
ZonegranZonisamide15$57,157
Emgality PenGalcanezumab-Gnlm43$41,820
Rasagiline Mesylate98$35,219
VimpatLacosamide28$30,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Neupro$947$249,298191 claims
SK Life Science, Inc.Xcopri$778$236,206199 claims
Acadia Pharmaceuticals IncNuplazid$582$120,71526 claims
Sunovion Pharmaceuticals Inc.Aptiom$294$107,18062 claims
AbbVieQulipta, Ubrelvy$4,005$105,68895 claims
BiogenAvonex (4 Pack)$486$102,90213 claims
E.r. Squibb & Sons, L.L.C.Zeposia$26$99,73412 claims
Amneal Pharmaceuticals LLCRytary$338$66,18547 claims
PfizerNurtec Odt$47$26,25720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 59 neurology providers in Idaho.

Other neurology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →